TRT Clinic Billing in 2026: The Low-T Compounding Risk Nobody's Pricing In

Billing J1071 on a Compounded Vial Is the Same False-Claims Problem the GLP-1 Clinics Already Got Caught In, and the DEA's Telehealth Clock Is Running Out

By Team Rcmaxis  ·  November 7, 2026  ·  10 min read

A low-T clinic bills J1071, the HCPCS code for testosterone cypionate, every time a patient comes in for a shot. What a lot of these clinics never confirm is whether the vial in the fridge is actually the FDA-approved, NDC-coded drug that code describes, or a cheaper version compounded by a 503A pharmacy down the street. That gap between what's billed and what's dispensed is exactly the pattern that turned compounded GLP-1 clinics into a false-claims story in 2025 and 2026. Testosterone clinics are running the same play, just one specialty behind, and most of them haven't noticed yet.

Add to that a DEA telehealth deadline sitting eight weeks out, and a payer landscape that pushes most TRT revenue to cash-pay in the first place, and you've got a specialty where the billing risk has almost nothing to do with coding accuracy and everything to do with what's actually in the syringe and how the patient got prescribed it.

The Codes: J1071, 96372, and the Diagnosis That Has to Back Them Up

When a clinic administers an FDA-approved testosterone cypionate injection in-office, the billing is straightforward on paper. J1071 (injection, testosterone cypionate, 1 mg) covers the drug itself, billed per milligram administered. 96372 covers the administration, the actual act of a clinician or clinical staff member giving the intramuscular injection. The supporting diagnosis is almost always E29.1 (testicular hypofunction), which covers both primary and secondary hypogonadism.

That's the easy part. Most commercial payers and Medicare Advantage plans don't pay for ongoing TRT on a single low lab value and a symptom checklist. The typical bar is two separate low-testosterone lab draws, usually morning total testosterone, plus documented symptoms consistent with hypogonadism, before a payer approves anything past the diagnostic workup. The American Urological Association's testosterone deficiency guideline backs a total testosterone cutoff below 300 ng/dL as a reasonable threshold, alongside a full symptom evaluation, PSA for men over 40, and a hematocrit check before therapy starts given the polycythemia risk. None of that is a payer requirement by default, but it's the clinical backbone that makes your prior auth packet hold up when a payer or auditor asks why this patient is on TRT at all. Pull your own payer's medical policy before you schedule a first injection expecting it to get paid, because lab-timing and documentation specifics vary payer to payer and a mismatch here is one of the most common reasons a TRT claim comes back denied.

The Compounding Trap: Billing a 503A Vial as If It Were the Branded Drug

Here's where TRT billing stops being a coding question and starts being a compliance one. A large share of testosterone telehealth platforms and cash-pay clinics don't dispense the FDA-approved product at all. They source compounded testosterone cypionate or enanthate from a 503A compounding pharmacy (which compounds for an individual patient based on a prescription) or a 503B outsourcing facility (which compounds at scale under different FDA oversight). FDA's bulk drug substance rules spell out specific, narrow conditions under which a substance can be compounded this way, and a finalized January 2025 interim policy tightened which substances qualify for both pathways.

A compounded product is not the same regulatory item as the branded, NDC-coded drug that J1071 describes, and billing it as if it were, especially to a federal health care program, misrepresents what was actually dispensed. This is the exact mechanism that's already created false-claims exposure on the compounded GLP-1 side: a clinic bills the code for the FDA-approved drug while a compounding pharmacy fills the actual order, and the gap between the two never gets reconciled until an auditor asks for pharmacy invoices next to claims data. Don't assume your compounding pharmacy's invoice language and your billing code are automatically consistent. Confirm exactly what's being dispensed, under what NDC or compounding designation, and bill according to that, not out of habit.

The DEA's December 31 Deadline: Telehealth-Only Prescribing Is Living on Borrowed Time

Testosterone is a Schedule III controlled substance, which normally triggers the Ryan Haight Act's requirement for an in-person evaluation before a controlled substance can be prescribed. That requirement has been waived on a temporary, repeatedly-renewed basis since the COVID-19 public health emergency. The DEA and HHS issued a fourth temporary extension, effective through December 31, 2026, that lets DEA-registered practitioners keep prescribing Schedule II through V controlled substances by telemedicine without a prior in-person exam, subject to the rule's conditions. A permanent framework, including a proposed special telemedicine registration pathway, is still being finalized and was not in effect as of this writing.

If your clinic's entire patient-acquisition model runs on telehealth-only intake, no in-person visit, no local clinic footprint, that flexibility is the thing keeping your prescribing model legal, and it has an expiration date sitting less than eight weeks from today. Nothing says it won't be extended a fifth time. Nothing guarantees it will be, either. Build a fallback now: know which of your patients and providers would need an in-person visit pathway if the waiver lapses, and don't let your entire revenue model depend on a temporary rule renewing itself indefinitely.

Why So Much of This Revenue Never Touches a Claim Form

Prior auth friction, inconsistent parity treatment, and payers that frame hypogonadism treatment as lifestyle rather than medically necessary all push TRT clinics toward a cash-pay membership model instead of fighting for insurance reimbursement on every patient. That's a real, common operating pattern across the specialty, not a loophole specific to any one clinic, and it changes what your RCM function actually needs to do. Lower claims volume doesn't mean lower compliance exposure. A cash-pay patient's chart still needs the same lab documentation, the same informed-consent and risk disclosure, and the same accurate description of what drug was dispensed, because an OIG or state board inquiry doesn't care whether a payer ever saw the claim. The compounding and controlled-substance risks above apply with equal force to a self-pay patient as they do to an insured one; the only difference is who's asking the questions when something goes wrong.

For the minority of visits that do route through insurance, make sure your scrubber rules account for the prior-auth lab requirements above before the claim goes out, not after the denial comes back. A first-pass denial on a TRT claim is almost always a documentation-timing problem, not a coding error, and it's cheaper to catch in the chart than to appeal after the fact.

OIG Scrutiny: What a Telehealth Hormone Clinic Audit Actually Looks For

TRT clinics sit squarely inside a category HHS-OIG has already flagged in writing. OIG's July 2022 Special Fraud Alert on arrangements with purported telemedicine companies came out the same day DOJ announced charges against multiple defendants in fraud schemes, including telehealth arrangements, that the department said totaled more than $1.2 billion. The alert lists several characteristics OIG treats as red flags, and more than one of them shows up routinely in the direct-to-consumer hormone clinic model:

• The clinic or marketing company, not the prescriber, selects which drug gets prescribed. If your intake flow is built to funnel every qualifying patient toward one product or one compounding source regardless of individual clinical fit, that's the pattern OIG is describing.
• Prescriber compensation tied to volume or to whether a prescription is written at all. A pay structure that rewards writing more scripts, rather than clinically appropriate ones, is a named risk factor.
• Aggressive, broad-based marketing, including social media ads, for a product or service covered by a federal health care program. Low-T and "male menopause" advertising has drawn direct scrutiny for overstating benefits while understating monitoring requirements; a Northwestern Medicine-affiliated study found that many direct-to-consumer testosterone platforms fail to convey the risks the AUA guideline says patients should be told about.
• Limited or no meaningful interaction between the prescriber and the patient before a prescription is written. A rubber-stamp telehealth visit that doesn't functionally evaluate the patient is the exact scenario the Ryan Haight in-person requirement exists to prevent.

None of this means legitimate telehealth TRT care is off the table. OIG says explicitly that the alert isn't meant to discourage real telehealth arrangements. It does mean your intake flow, your prescriber compensation structure, and your marketing claims are all fair game in a post-payment review, and Medicare's standard lookback for that kind of review runs 36 months from the date of service, longer if fraud is alleged. Run your own arrangement against the list above before a federal reviewer does.

Frequently Asked Questions About TRT and Men's Health Clinic Billing

Can you bill J1071 for compounded testosterone?

Not the way most clinics assume. J1071 describes testosterone cypionate, 1 mg, as an FDA-approved, NDC-coded drug. A compounded version made by a 503A pharmacy for a specific patient, or by a 503B outsourcing facility, is a different product under FDA's compounding rules, and billing it under J1071 as if it were the branded NDC item misrepresents what was actually dispensed. Confirm with your pharmacy exactly what's being supplied and bill according to your payer's compounded-drug billing instructions, not by default habit.

Do testosterone clinics need prior authorization for TRT?

Most commercial payers and Medicare Advantage plans require it, and the usual bar is two separate low-testosterone lab draws, typically morning total testosterone, plus documented symptoms consistent with hypogonadism (E29.1) before approving ongoing therapy. Exact lab-timing and symptom-documentation rules vary by payer, so confirm the specific policy before you schedule a patient's first injection expecting coverage.

Can testosterone still be prescribed by telehealth without an in-person exam?

Through December 31, 2026, yes. The DEA and HHS issued a fourth temporary extension, effective through that date, letting DEA-registered practitioners prescribe Schedule III controlled substances, including testosterone, by telemedicine without a prior in-person evaluation. A permanent framework, including a special telemedicine registration pathway, is still being finalized. If your intake flow depends entirely on telehealth-only prescribing, build a contingency for what happens if the flexibility isn't extended again.